Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
NOS3 4846 ARGININE CHEMBL1485 DrugBank 16720041, 16717106, 16682803, 16690332, 16729278
NOS3 4846 MICONAZOLE CHEMBL91 inhibitor DrugBank 7518297, 7683652, 7536941, 9873034
NOS3 4846 CHEMBL457530 CHEMBL457530 DrugBank 10592235
NOS3 4846 CHEMBL479014 CHEMBL479014 DrugBank 17139284, 17016423, 10592235
NOS3 4846 ETHYLISOTHIOUREA CHEMBL321691 DrugBank 17139284, 17016423, 10592235
NOS3 4846 L-NIO CHEMBL11471 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CHEMBL483091 CHEMBL483091 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CHEMBL165372 CHEMBL165372 DrugBank 17139284, 17016423
NOS3 4846 CHEMBL323202 CHEMBL323202 DrugBank 10592235
NOS3 4846 CHEMBL1230023 CHEMBL1230023 DrugBank 10592235
NOS3 4846 CHEMBL230153 CHEMBL230153 DrugBank 10592235
NOS3 4846 HYDROCHLOROTHIAZIDE CHEMBL435 PharmGKB
NOS3 4846 SAPROPTERIN CHEMBL1201774 cofactor TdgClinicalTrial, TEND, DrugBank 10749876, 12003347, 10075731, 11009561, 10995244, 10924132, 17139284, 17016423, 10592235
NOS3 4846 CHEMBL444422 CHEMBL444422 DrugBank 10592235
NOS3 4846 7-NITROINDAZOLE CHEMBL247378 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CACODYLIC ACID CHEMBL1231644 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CHEMBL260629 CHEMBL260629 DrugBank 17139284, 17016423, 10592235
NOS3 4846 APREMILAST CHEMBL514800 DrugBank
NOS3 4846 CHEMBL526688 CHEMBL526688 DrugBank 10592235
NOS3 4846 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
NOS3 4846 CANAVANINE CHEMBL443732 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CLOPROSTENOL (CHEMBL2220404) CHEMBL2220404 DrugBank 10592235
NOS3 4846 CHEMBL589752 CHEMBL589752 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CHEMBL420671 CHEMBL420671 DrugBank 10592235
NOS3 4846 CHEMBL474637 CHEMBL474637 DrugBank 10592235
NOS3 4846 FLUOROURACIL CHEMBL185 PharmGKB
NOS3 4846 VINCRISTINE CHEMBL90555 PharmGKB
NOS3 4846 CHEMBL44833 CHEMBL44833 DrugBank 17139284, 17016423, 10592235
NOS3 4846 1400W CHEMBL107251 DrugBank 10592235
NOS3 4846 CHEMBL362148 CHEMBL362148 DrugBank 17139284, 17016423, 10592235
NOS3 4846 CHEMBL54277 CHEMBL54277 DrugBank 17139284, 17016423
NOS3 4846 CHEMBL107201 CHEMBL107201 DrugBank 10592235
NOS3 4846 CYTARABINE CHEMBL803 PharmGKB
NOS3 4846 PREDNISONE CHEMBL635 PharmGKB
NOS3 4846 THIOUREA CHEMBL260876 TdgClinicalTrial
NOS3 4846 L-CITRULLINE CHEMBL444814 DrugBank 10440125, 10403604, 10749853, 10690351, 10460702

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
NOS3 rs1799983 GG salbutamol efficacy no No significant differences in the change in digital volume pulse parameters - reflection index and stiffness index - before and after salbutamol administration were seen between the two genotype groups. This indicates that this SNP does not affect salbutamol-evoked endothelium-dependent vasodilation. Genotype GG is not associated with response to salbutamol in healthy individuals as compared to genotypes GT + TT. 23543259 1183682080
NOS3 rs1799983 G cyclophosphamide efficacy no Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T. 29938344 1449576797
NOS3 rs2070744 CC + CT sildenafil efficacy yes This effect was only seen in the subset of patients with post-operative ED rather than organic, clinical ED. Genotypes CC + CT are associated with increased response to sildenafil in men with Erectile Dysfunction as compared to genotype TT. 22064666 827783711
NOS3 rs1799983 GG enalapril efficacy no No association was found between this SNP and response to enalapril. Genotype GG is not associated with response to enalapril in people with Hypertension as compared to genotypes GT + TT. 22706620 1183690865
NOS3 rs2070744 CC + CT enalapril efficacy yes Patients with the CC or CT genotypes showed significantly larger decreases in systolic and diastolic blood pressure as compared to patients with the TT genotype. Genotypes CC + CT are associated with increased response to enalapril in people with Hypertension as compared to genotype TT. 22706620 1183690860
NOS3 rs2070744 TT salbutamol efficacy no No significant differences in the change in digital volume pulse parameters - reflection index and stiffness index - before and after salbutamol administration were seen between the two genotype groups. This indicates that this SNP does not affect salbutamol-evoked endothelium-dependent vasodilation. Genotype TT is not associated with response to salbutamol in healthy individuals as compared to genotypes CC + CT. 23543259 1183682086
NOS3 rs1799983 G epirubicin efficacy not stated Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms. 25545243 1444694895
NOS3 rs1799983 GG salvianolic acid b efficacy yes Those with the GG genotype were found to have a much better response to salvianolate as compared to those who carried the T allele. Response was assessed by the decrease in the number or severity of angina attacks and nitroglycerine consumption. Genotype frequencies also significantly differed when comparing healthy controls (n=198) with patients with coronary heart disease (n=153). Genotype GG is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes GT + TT. 24827774 1445296275